Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial (LUMEN1)
Sponsor: University Hospital, Basel, Switzerland
Terminated
The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.
Other terminated trials from University Hospital, Basel, Switzerland
- Analysis Transmission Rate · Jan 2025
- Acne Lesions · Sep 2024
- Diabetes Mellitus Type 2 in Obese · Phase PHASE2 · May 2024
- Delirium · Phase PHASE4 · Feb 2023
- Pelvic Pain · Phase NA · Jul 2022
See all terminations from University Hospital, Basel, Switzerland
This NA trial investigates MEN1 Gene Mutation and is currently terminated or withdrawn. University Hospital, Basel, Switzerland leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Dec 2025 [monthly]
Recruiting NA
-
Sep 2024 — Feb 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jul 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jul 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Basel, Switzerland
For direct contact, visit the study record on ClinicalTrials.gov .